Generali France becomes strategic partner of health-tech start-up
Remedee Labs, a French start-up that has developed a global and innovative solution for the management of chronic pain, has found a new investment and strategic partner in Generali France. This partnership will accelerate the dissemination of the Company’s solutions in France and worldwide.
Generali France, which has a strong presence in the health insurance and individual and group pension markets, is investing in Remedee Labs, a French start-up that has developed a global and innovative solution for the management of chronic pain. With this investment, Generali becomes not only a shareholder but also a strategic partner of the company, which at the same time will be able to reach a greater number of people, and to improve their quality of life while optimising healthcare costs.
It is estimated that at least 12 million people in France suffer from some form of chronic pain; however, 70% of them don’t receive an adequate treatment. As a result,their quality of life is severely compromised1. Remedee Labs has the ambition to change the quality of life of its patients and has developed a global and innovative solution to manage chronic pain. It combines its unique, non-invasive millimetre wave neuromodulation technology (via an endorphin stimulating wristband) with a digital service platform2 and a personalised, multidisciplinary support.
With the funds increased of 12,2 million euros by Generali France, its historical investors (HCVC, Habert Dassault Finance) and private investors as well as BPI and its partner banks, Remedee Labs is willing to expand its market in France and internationally, while continuing to develop its neuromodulation technology in order to better meet the needs of patients, physicians and health insurers.
“The innovative solution developed by Remedee Labs addresses a real need in the management of chronic pain and will provide significant added value to our customers. Our involvement in Future4Care is bearing fruit and we see the richness of this ecosystem, giving us access to successful and relevant start-ups in connected health and personalised medicine. This enrichment of our service offer will be proposed to the beneficiaries of the Health and Welfare social action as well as to our 8,000 Colleagues, Employees and General Agents”, said Emmanuel Néré, Innovation Director of Generali France.
Millimetre waves endorphin stimulation, an alternative treatment for chronic pain
Remedee Labs has developed the first non-invasive neuromodulation solution to transform the treatment of chronic pain.
Resulting from many years of scientific research and strong partnerships (CEA-Leti, ST Microelectronics), this technology is based on the implanted MEET (Microelectronic Endorphin Trigger) module, the first miniaturised millimetre wave emission module. Integrated into a waistband and positioned on the wrist, this module sends a very high frequency electronic signal that stimulates the subcutaneous receptor (0.5 mm under the skin) with great precision.
In response to this painless nerve stimulation, the brain releases intracerebral endorphins, which have the effect of relieving pain, reducing stress and improving sleep.
To know more about Remedee Labs, you can find more information here.
For more information about Generali France, please click here.
1 Livre Blanc de la Douleur SFETD 2017